#ESMO26 DeLLphi-305: tarlatamab+durva vs durva, 1L maintenance ES-SCLC
➡️ OS 21.1 vs 12.7 mo, HR 0.42
➡️ PFS 7.4 vs 1.9 mo, HR 0.34
➡️ CRS 49.6% (G3+ 0.4%)
Amazing to be part of this practice-changing study on the global steering committee!!
@LungCancerRx @OncoAlert @oncodaily
256 浏览 · 7 赞 · 4 转发 · 1 回复
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Ashray Maniar@ManiarAshray
@ADesaiMD @LungCancerRx @OncoAlert @oncodaily @sands_jacob @drshieldsmd @AnaVManana @DevikaDasMD @GlopesMd @RManochakian @FawziAbuRous @lungoncdoc @LaurenByersMD @SuyogCancer Great OS results, excited to see and hopefully propels more outpt tarlatamab protocols. I assume that the PFS and ORR are based on the first maintenance cycle instead of initiation of therapy?
来源：Aakash Desai · x.com